Endometrial effect of transdermal estradiol and progestin ST-1435 in postmenopausal women.

Abstract

OBJECTIVE:

To study the endometrial effect of the transdermal synthetic progestin ST-1435.

DESIGN:

Prospective.

SETTING:

City Maternity Hospital, Helsinki, Finland.

PATIENTS:

Eleven postmenopausal women used transdermal estradiol (E2) patches for 6 weeks immediately before a vaginal operation for prolapse. For the last 10 days, 1 mg of ST-1435 transdermally in a gel was combined to the treatment.

MAIN OUTCOME MEASURES:

Blood samples were taken to follow serum concentrations of E2, follicle-stimulating hormone, and ST-1435. Endometrial samples for histologic examination were collected during the operation to evaluate the effect of the progestin.

RESULTS:

Transdermal absorption of ST-1435 resulted in reasonably constant serum concentrations of ST-1435 in each subject. A progestin effect on the endometrium was seen in 9 of 10 samples obtained. One sample did not show any progestin effect in spite of adequate ST-1435 levels, but this patient's E2 concentrations were low.

CONCLUSIONS:

When the estrogen stimulation was adequate, the transdermal ST-1435 induced a progestin effect on the endometrium, i.e., it had an end-organ effect.

• Authors: S Suhonen, M Haukkamaa, P Lähteenmäki, T Holmström
• Journal: Fertility and sterility (Fertil Steril) Vol. 57 Issue 6 Pg. 1211-5 (Jun 1992) ISSN: 0015-0282 [Print] United States
• PMID: 1601141 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Norprogesterones
• Estradiol
• ST 1435
• Follicle Stimulating Hormone

Topics

• Administration, Cutaneous
• Aged
• Endometrium (drug effects, pathology)
• Estradiol (blood, therapeutic use)
• Estrogen Replacement Therapy
• Female
• Follicle Stimulating Hormone (blood)
• Humans
• Middle Aged
• Norprogesterones (blood, therapeutic use)
• Osmolar Concentration